Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-stroke depression.

J W Tiller1

  • 1Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia.

Psychopharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Post-stroke depression affects up to 30% of patients and impacts recovery. Moclobemide shows promise as a well-tolerated antidepressant for this population.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The identification and treatment of depression by general practitioners.

The Australian and New Zealand journal of psychiatry·2002
Same author

Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2000
Same author

Cade's observation of the antimanic effect of lithium and early Australian research.

The Australian and New Zealand journal of psychiatry·2000
Same author

An open study of sertraline in patients with major depression who failed to respond to moclobemide.

The Australian and New Zealand journal of psychiatry·2000
Same author

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.

European archives of psychiatry and clinical neuroscience·1999
Same author

Liability in prescribing choice: the example of the antidepressants.

The Australian and New Zealand journal of psychiatry·1998
Same journal

Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

Psychopharmacology·2026
Same journal

Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

Psychopharmacology·2026
Same journal

Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

Psychopharmacology·2026
Same journal

Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

Psychopharmacology·2026
Same journal

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Psychopharmacology·2026
Same journal

OPRD1 rs4654327 and Outcomes of Extended-Release Naltrexone in Alcohol Use Disorder: An Exploratory Prospective Pharmacogenetic Study.

Psychopharmacology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Neurology

Background:

  • Depression affects 25-30% of stroke patients, extending beyond mere disability response.
  • Severity correlates with lesion location: left anterior frontal pole proximity worsens depression, while right hemisphere lesions show an inverse relationship.
  • Untreated post-stroke depression can persist for over 7-8 months, hindering social and physical activity resumption.

Purpose of the Study:

  • To investigate the characteristics and treatment of depression following stroke.
  • To evaluate the potential of moclobemide as a well-tolerated and effective antidepressant for stroke survivors.

Main Methods:

  • Correlation analysis of depression severity with lesion location in stroke patients.
  • Review of antidepressant efficacy and side-effect profiles in the context of post-stroke depression.

Related Experiment Videos

  • Assessment of moclobemide's tolerability and efficacy based on its known properties.

    • Main Results:

    • Depression severity is linked to the specific brain region affected by the stroke.
    • Standard antidepressants may have limited value due to side effects or toxicity in stroke patients.
    • Moclobemide demonstrates potential for good tolerability and efficacy in treating both endogenous and reactive depressions in this cohort.

    Conclusions:

    • Post-stroke depression is a significant issue impacting patient recovery and quality of life.
    • Moclobemide's favorable side-effect profile suggests it may be a suitable treatment option for stroke patients experiencing depression.
    • Further clinical evaluation is warranted to confirm moclobemide's efficacy and safety in this patient group.